The long‐term outcome of patients with polycystic liver disease treated with lanreotide

Aliment Pharmacol Ther 2012; 35: 266–274

[1]  M. Mercado,et al.  Liver transplantation for polycystic liver disease. , 2014, Journal of the American College of Surgeons.

[2]  F. Nevens,et al.  Systematic review: the pathophysiology and management of polycystic liver disease , 2011, Alimentary pharmacology & therapeutics.

[3]  Mohid S. Khan,et al.  Long‐term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) , 2011, Alimentary pharmacology & therapeutics.

[4]  M. V. van Oijen,et al.  Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  D. Nagorney,et al.  Medical and surgical treatment options for polycystic liver disease 1 , 2010, Hepatology.

[6]  J. Drenth,et al.  Congenital fibrocystic liver diseases. , 2010, Best practice & research. Clinical gastroenterology.

[7]  James Glockner,et al.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.

[8]  L. Antiga,et al.  Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[9]  L. van Keimpema,et al.  Effect of octreotide on polycystic liver volume , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[10]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .

[11]  M. V. van Oijen,et al.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.

[12]  N. LaRusso,et al.  The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD) , 2009, Hepatology.

[13]  N. LaRusso,et al.  Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. , 2008, The American journal of pathology.

[14]  L. van Keimpema,et al.  Somatostatin analogues reduce liver volume in polycystic liver disease , 2008, Gut.

[15]  R. Laheij,et al.  Evaluation of a Gastrointestinal Symptoms Questionnaire , 2006, Digestive Diseases and Sciences.

[16]  Paul A Thompson,et al.  Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[17]  N. LaRusso,et al.  Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. , 2003, American journal of physiology. Cell physiology.

[18]  D. Alvaro,et al.  Regulation and deregulation of cholangiocyte proliferation. , 2000, Journal of hepatology.

[19]  J. Larson.  The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.

[20]  A. Stanson,et al.  Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. , 1994, Journal of the American Society of Nephrology : JASN.

[21]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[22]  L. van Keimpema,et al.  Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. , 2011, Annals of surgery.

[23]  V. Torres.  Polycystic liver disease. , 1995, Contributions to nephrology.

[24]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .